- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348149
Lindera Obtusiloba for Non-small Cell Lung Cancer
April 13, 2020 updated by: Jun-Yong Choi
Adjunctive Administration of Lindera Obtusiloba on Non-small Cell Lung Cancer Patients Who Receive PD-1 Inhibitors: a Randomized Exploratory Pilot Study
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jun-Yong Choi, KMD/PHD
- Phone Number: +82-55-360-5953
- Email: orientdoct@gmail.com
Study Locations
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Korea, Republic of, 50612
- Recruiting
- Korean Medicine Hospital, Pusan National University
-
Contact:
- Jun-Yong Choi
- Email: kmd@pusan.ac.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged ≥ 20 years
- Patients who have understood and signed the informed consent.
- Subjects who have been confirmed histologically and radiologically for non small cell lung cancer and are scheduled to receive treatment with immune checkpoint inhibitors
- Subjects whose urine HCG are negative and who have agreed with the appropriate method of contraception in case of women of childbearing potential
- Subjects who can fully communicate with their medical doctor about their symptoms or quality of life and who can fill out questionnaires
- Subjects who can follow up during the clinical trial
- Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
- Hemoglobin ≥ 9g/dL
Exclusion Criteria:
- Subjects who are pregnant, breastfeeding, planning to become pregnant or women of childbearing potential who do not agree with the appropriate method of contraception
- Subjects who have symptomatic and uncontrolled brain or central nervous system metastasis
- Subjects who complain of uncontrolled pain despite using analgesics
- Diastolic Blood Pressure>100mmHg or Systolic Blood Pressure>160mmHg
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels higher than 2.5 times the upper limit for normal
- Creatinine level higher than 1.5 times the upper limit for normal
- Subjects who have participated in other clinical trials within 1 months
- Subjects with a history of serious drug allergies or who have hypersensitivity to the Investigational Product (the main ingredient and its components)
- Subjects with autoimmune diseases
- Subjects who have alcoholism or drug dependence
- Subjects who have cognitive impairment or psychiatric problems
- Subjects who have undergone surgery within 2 weeks
- Subjects who took other herbal medicine or other medicines within 4 weeks
- Subjects who have a medical condition that is likely to affect results or who are determined to be inappropriate to participate in this clinical trial at the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
|
One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder.
Participants intake one package per day for 8 weeks.
|
No Intervention: Wait-list
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EORTC QLQ-C30
Time Frame: Change from baseline to 6-week and 8-week
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)
|
Change from baseline to 6-week and 8-week
|
EORTC QLQ-LC13
Time Frame: Change from baseline to 6-week and 8-week
|
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
|
Change from baseline to 6-week and 8-week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
NK cell percentage in peripheral blood
Time Frame: Change from baseline to 8-week
|
Change from baseline to 8-week
|
CD4+/CD8+ T cell in peripheral blood
Time Frame: Change from baseline to 8-week
|
Change from baseline to 8-week
|
total T cell, T-helper cell, T-suppressor cell and B-cell percentage in peripheral blood
Time Frame: Change from baseline to 8-week
|
Change from baseline to 8-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jun-Yong Choi, KMD/PHD, Korean Medicine Hospital of Pusan National University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 28, 2018
Primary Completion (Anticipated)
December 27, 2020
Study Completion (Anticipated)
December 27, 2020
Study Registration Dates
First Submitted
April 10, 2020
First Submitted That Met QC Criteria
April 13, 2020
First Posted (Actual)
April 16, 2020
Study Record Updates
Last Update Posted (Actual)
April 16, 2020
Last Update Submitted That Met QC Criteria
April 13, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PNUKHIRB-2018012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Lindera obtusiloba extract
-
Han Wha Pharma Co., Ltd.UnknownDiabetic ComplicationKorea, Republic of
-
University Hospitals Cleveland Medical CenterUnknownAsthma | Allergic Rhinitis | Allergic ConjunctivitisUnited States
-
Access Business GroupCompleted
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumCompletedAsthma | Perennial Allergic RhinitisUnited States
-
SeppicRecruiting
-
Mahidol UniversityCompleted
-
Unilever R&DCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingBreast CarcinomaUnited States
-
Activ'insideCIC SANPSY (USR CNRS 3413), Groupe Hospitalier Pellegrin, Bordeaux, FranceCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedChronic Arsenic PoisoningBangladesh